Zydus Lifesciences to develop world's first dual vaccine for typhoid

Typhoid and shigellosis remain serious public health threats, particularly in low-resource settings

Zydus Lifesciences is set to develop the world’s first combination vaccine for typhoid and shigellosis. The initiative, backed by the Bill & Melinda Gates Foundation, aims to protect infants and children in endemic regions.

 

This vaccine, the first of its kind, if successful, could revolutionise childhood immunisation programmes, offering a cost-effective and efficient solution to two major public health concerns.

 

Leveraging its World Health Organization (WHO)-prequalified Typhoid Conjugate Vaccine (ZyVac TCV) and a Shigella vaccine from its undisclosed partner, Zydus will conduct early-stage research, animal immunogenicity studies, and regulatory preclinical toxicology evaluations. The project is expected to commence in March